title: Long-term response with sunitinib for metastatic renal cell carcinoma.
abstract: A 65-year-old man with metastatic renal cell carcinoma developed progressive disease after treatment with interferon-alpha. He began treatment with sunitinib, a multitargeted tyrosine kinase inhibitor, on clinical trial. The patient achieved a partial response after two cycles of therapy, with a durable response continuing after 2 years of treatment. This case report illustrates the long-term response to sunitinib for patients with metastatic renal cell carcinoma.
authors.affiliation: Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
authors.forename: Ellen A
authors.initials: EA
authors.lastname: Ronnen
authors.forename: G Varuni
authors.initials: GV
authors.lastname: Kondagunta
authors.forename: Michelle S
authors.initials: MS
authors.lastname: Ginsberg
authors.forename: Paul
authors.initials: P
authors.lastname: Russo
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Motzer
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D011758:Pyrroles / Q000627:therapeutic use*; D012074:Remission Induction; D000077210:Sunitinib; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib